Abstract
Objective To evaluate the effects of Zhuangyang capsule added on risperidone on cognition, symptoms and social function in chronic schizophrenia patients. Methods All 200 chronic schizophrenic patients who met the DSM-1V criteria for schizophrenia were randomized to receive 8 week treatment with either Zhuangyang capsule (trial group, n = 100) or placebo (control group, n = 100) added on risperidone. The symptoms were assessed with measurement including the Scale for the Assessment of Positive Symptoms(SAPS) and Scale for the Assessment of Negative Symptoms(SANS) and the cognition was assessed with the Wisconsin Card Sorting Test (WCST), while the social function with the Social Disability Screening Schedule (SDSS). Results Significant within-group improvements were observed in SAPS,SANS, WCST (except perseveringly responses number of trial group) and SDSS in 2 groups at the endpoint of week 8 (all P <0.01). The improvement in SAPS and SANS in trial group were more than that in control group(P<0.01). There were significant differences between 2 groups in the improvements of WCST parameters from baseline to weeks 8, including number of completed categories [trial group of (1.2 ± 1.9)versus control group of (0.7 ± 1.4)], right responses number [(10.5 ± 16.3) versus (5.3 ± 16.9)],error responses number [(15.3±25.9) versus (7.2±23.7)], conceptual level [(15.1±23.0) versus (9.5±26.7)]and social function[(6.3±4.5) versus (4.9±3.9)] (P<0.05 or<0.01). Conclusion The adjunct therapy of Zhuangyang Capsule to risperidone is effective in improvement of cognitive function, symptoms and social function in chronic schizophrenic patients. Key words: Schizophrenia; Risperidone; YANG-REINFORCING DRUGS; Cognition; Social adjustment
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call